ENZN — Enzon Pharmaceuticals Income Statement
0.000.00%
- $11.13m
- -$34.86m
- 68
- 54
- 43
- 55
Annual income statement for Enzon Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.207 | 0.052 | 0.701 | 0.026 | 0 |
Selling / General / Administrative Expenses | |||||
Total Operating Expenses | 1.18 | 1.36 | 1.17 | 1.06 | 1.04 |
Operating Profit | -0.973 | -1.3 | -0.469 | -1.03 | -1.04 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.973 | -1.3 | -0.462 | -0.386 | 1.22 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.979 | -1.31 | -0.469 | -0.186 | 1.37 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.979 | -1.31 | -0.469 | -0.186 | 1.37 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.979 | -1.77 | -2.49 | -1.46 | 0.098 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.022 | -0.035 | -0.034 | -0.02 | 0.001 |
Dividends per Share | |||||
Special Dividends per Share |